Peanut oral immunotherapy plus omalizumab for 24 weeks safely induced tolerance at 48 weeks in allergic adults

Peanut oral immunotherapy (POIT) with or without omalizumab can improve tolerance in children. Data on adults are limited. We evaluated the safety and efficacy of POIT, combined with omalizumab, over 48 weeks in adults.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research